Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern
The emergency of new SARS-CoV-2 variants that feature increased immune escape marks an urgent demand for better vaccines that will provide broader immunogenicity. Here, we evaluated the immunogenic capacity of vaccine candidates based on the recombinant trimeric spike protein (S) of different SARS-C...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1020159/full |
| _version_ | 1811181589826109440 |
|---|---|
| author | Erika Rudi Pablo Martin Aispuro Eugenia Zurita Maria M. Gonzalez Lopez Ledesma Daniela Bottero Juan Malito Magali Gabrielli Emilia Gaillard Matthew Stuible Yves Durocher Andrea V. Gamarnik Andrés Wigdorovitz Daniela Hozbor |
| author_facet | Erika Rudi Pablo Martin Aispuro Eugenia Zurita Maria M. Gonzalez Lopez Ledesma Daniela Bottero Juan Malito Magali Gabrielli Emilia Gaillard Matthew Stuible Yves Durocher Andrea V. Gamarnik Andrés Wigdorovitz Daniela Hozbor |
| author_sort | Erika Rudi |
| collection | DOAJ |
| description | The emergency of new SARS-CoV-2 variants that feature increased immune escape marks an urgent demand for better vaccines that will provide broader immunogenicity. Here, we evaluated the immunogenic capacity of vaccine candidates based on the recombinant trimeric spike protein (S) of different SARS-CoV-2 variants of concern (VOC), including the ancestral Wuhan, Beta and Delta viruses. In particular, we assessed formulations containing either single or combined S protein variants. Our study shows that the formulation containing the single S protein from the ancestral Wuhan virus at a concentration of 2µg (SW2-Vac 2µg) displayed in the mouse model the highest IgG antibody levels against all the three (Wuhan, Beta, and Delta) SARS-CoV-2 S protein variants tested. In addition, this formulation induced significantly higher neutralizing antibody titers against the three viral variants when compared with authorized Gam-COVID-Vac-rAd26/rAd5 (Sputnik V) or ChAdOx1 (AstraZeneca) vaccines. SW2-Vac 2µg was also able to induce IFN-gamma and IL-17, memory CD4 populations and follicular T cells. Used as a booster dose for schedules performed with different authorized vaccines, SW2-Vac 2µg vaccine candidate also induced higher levels of total IgG and IgG isotypes against S protein from different SARS-CoV-2 variants in comparison with those observed with homologous 3-dose schedule of Sputnik V or AstraZeneca. Moreover, SW2-Vac 2µg booster induced broadly strong neutralizing antibody levels against the three tested SARS-CoV-2 variants. SW2-Vac 2µg booster also induced CD4+ central memory, CD4+ effector and CD8+ populations. Overall, the results demonstrate that SW2-Vac 2 µg is a promising formulation for the development of a next generation COVID-19 vaccine. |
| first_indexed | 2024-04-11T09:20:00Z |
| format | Article |
| id | doaj.art-14d1a1430e014487bd19f03884315941 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T09:20:00Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-14d1a1430e014487bd19f038843159412022-12-22T04:32:14ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.10201591020159Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concernErika Rudi0Pablo Martin Aispuro1Eugenia Zurita2Maria M. Gonzalez Lopez Ledesma3Daniela Bottero4Juan Malito5Magali Gabrielli6Emilia Gaillard7Matthew Stuible8Yves Durocher9Andrea V. Gamarnik10Andrés Wigdorovitz11Daniela Hozbor12Laboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaLaboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaLaboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaFundación Instituto Leloir-IIBBA CONICET, Buenos Aires, ArgentinaLaboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaINCUINTA INTA, CONICET, HURLINGHAM, INTA Castelar, Buenos Aires, ArgentinaLaboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaLaboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaHuman Health Therapeutics Research Center, National Research Council Canada, Montreal, QC, CanadaHuman Health Therapeutics Research Center, National Research Council Canada, Montreal, QC, CanadaFundación Instituto Leloir-IIBBA CONICET, Buenos Aires, ArgentinaINCUINTA INTA, CONICET, HURLINGHAM, INTA Castelar, Buenos Aires, ArgentinaLaboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Centro Científico Tecnológico – Consejo Nacional de Investigaciones Científicas y Técnicas (CCT-CONICET), La Plata, ArgentinaThe emergency of new SARS-CoV-2 variants that feature increased immune escape marks an urgent demand for better vaccines that will provide broader immunogenicity. Here, we evaluated the immunogenic capacity of vaccine candidates based on the recombinant trimeric spike protein (S) of different SARS-CoV-2 variants of concern (VOC), including the ancestral Wuhan, Beta and Delta viruses. In particular, we assessed formulations containing either single or combined S protein variants. Our study shows that the formulation containing the single S protein from the ancestral Wuhan virus at a concentration of 2µg (SW2-Vac 2µg) displayed in the mouse model the highest IgG antibody levels against all the three (Wuhan, Beta, and Delta) SARS-CoV-2 S protein variants tested. In addition, this formulation induced significantly higher neutralizing antibody titers against the three viral variants when compared with authorized Gam-COVID-Vac-rAd26/rAd5 (Sputnik V) or ChAdOx1 (AstraZeneca) vaccines. SW2-Vac 2µg was also able to induce IFN-gamma and IL-17, memory CD4 populations and follicular T cells. Used as a booster dose for schedules performed with different authorized vaccines, SW2-Vac 2µg vaccine candidate also induced higher levels of total IgG and IgG isotypes against S protein from different SARS-CoV-2 variants in comparison with those observed with homologous 3-dose schedule of Sputnik V or AstraZeneca. Moreover, SW2-Vac 2µg booster induced broadly strong neutralizing antibody levels against the three tested SARS-CoV-2 variants. SW2-Vac 2µg booster also induced CD4+ central memory, CD4+ effector and CD8+ populations. Overall, the results demonstrate that SW2-Vac 2 µg is a promising formulation for the development of a next generation COVID-19 vaccine.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1020159/fullCOVID-19SARS-CoV-2mice immunizationspike trimeric proteinimmunogenicityvaccine candidate |
| spellingShingle | Erika Rudi Pablo Martin Aispuro Eugenia Zurita Maria M. Gonzalez Lopez Ledesma Daniela Bottero Juan Malito Magali Gabrielli Emilia Gaillard Matthew Stuible Yves Durocher Andrea V. Gamarnik Andrés Wigdorovitz Daniela Hozbor Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern Frontiers in Immunology COVID-19 SARS-CoV-2 mice immunization spike trimeric protein immunogenicity vaccine candidate |
| title | Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern |
| title_full | Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern |
| title_fullStr | Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern |
| title_full_unstemmed | Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern |
| title_short | Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern |
| title_sort | immunological study of covid 19 vaccine candidate based on recombinant spike trimer protein from different sars cov 2 variants of concern |
| topic | COVID-19 SARS-CoV-2 mice immunization spike trimeric protein immunogenicity vaccine candidate |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1020159/full |
| work_keys_str_mv | AT erikarudi immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT pablomartinaispuro immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT eugeniazurita immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT mariamgonzalezlopezledesma immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT danielabottero immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT juanmalito immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT magaligabrielli immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT emiliagaillard immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT matthewstuible immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT yvesdurocher immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT andreavgamarnik immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT andreswigdorovitz immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern AT danielahozbor immunologicalstudyofcovid19vaccinecandidatebasedonrecombinantspiketrimerproteinfromdifferentsarscov2variantsofconcern |